123 related articles for article (PubMed ID: 38376291)
21. TTF-1/Nkx2.1 functional connection with mutated EGFR relies on LRIG1 and β-catenin pathways in lung cancer cells.
Zamboni M; Civitareale D
Biochem Biophys Res Commun; 2018 Nov; 505(4):1027-1031. PubMed ID: 30314701
[TBL] [Abstract][Full Text] [Related]
22. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
Guo D; Nilsson J; Haapasalo H; Raheem O; Bergenheim T; Hedman H; Henriksson R
Acta Neuropathol; 2006 Mar; 111(3):238-46. PubMed ID: 16532360
[TBL] [Abstract][Full Text] [Related]
23. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.
Krig SR; Frietze S; Simion C; Miller JK; Fry WH; Rafidi H; Kotelawala L; Qi L; Griffith OL; Gray JW; Carraway KL; Sweeney C
Mol Cancer Res; 2011 Oct; 9(10):1406-17. PubMed ID: 21821674
[TBL] [Abstract][Full Text] [Related]
24. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O
Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959
[TBL] [Abstract][Full Text] [Related]
25. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.
Guo D; Han L; Shu K; Chen J; Lei T
J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):91-4. PubMed ID: 17393120
[TBL] [Abstract][Full Text] [Related]
28. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.
Shattuck DL; Miller JK; Laederich M; Funes M; Petersen H; Carraway KL; Sweeney C
Mol Cell Biol; 2007 Mar; 27(5):1934-46. PubMed ID: 17178829
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
30. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.
Ji Y; Kumar R; Gokhale A; Chao HP; Rycaj K; Chen X; Li Q; Tang DG
Semin Cancer Biol; 2022 Jul; 82():120-133. PubMed ID: 33476721
[TBL] [Abstract][Full Text] [Related]
31. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H
Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604
[TBL] [Abstract][Full Text] [Related]
32.
Succony L; Gómez-López S; Pennycuick A; Alhendi ASN; Davies D; Clarke SE; Gowers KHC; Wright NA; Jensen KB; Janes SM
Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34385275
[TBL] [Abstract][Full Text] [Related]
33. Single-molecule array assay reveals the prognostic impact of plasma LRIG1 in ovarian carcinoma.
de Melo ALL; Linder A; Sundfeldt K; Lindquist D; Hedman H
Acta Oncol; 2022 Nov; 61(11):1425-1433. PubMed ID: 36326616
[TBL] [Abstract][Full Text] [Related]
34. Expression of γH2AX may help in defining a genetically more stable subtype of infiltrating ductal carcinoma of breast.
Bhatia A; Dey P; Goel S; Singh G
Indian J Med Res; 2013 Apr; 137(4):759-66. PubMed ID: 23703345
[TBL] [Abstract][Full Text] [Related]
35. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.
Goldoni S; Iozzo RA; Kay P; Campbell S; McQuillan A; Agnew C; Zhu JX; Keene DR; Reed CC; Iozzo RV
Oncogene; 2007 Jan; 26(3):368-81. PubMed ID: 16847455
[TBL] [Abstract][Full Text] [Related]
36. LRIG1 enhances chemosensitivity by modulating BCL-2 expression and receptor tyrosine kinase signaling in glioma cells.
Guo Z; Chen Q; Liu B; Tian D; Zhang S; Li M
Yonsei Med J; 2014 Sep; 55(5):1196-205. PubMed ID: 25048475
[TBL] [Abstract][Full Text] [Related]
37. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
[TBL] [Abstract][Full Text] [Related]
38. A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors.
Faraz M; Herdenberg C; Holmlund C; Henriksson R; Hedman H
J Biol Chem; 2018 Mar; 293(9):3421-3435. PubMed ID: 29317492
[TBL] [Abstract][Full Text] [Related]
39. LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.
Kou C; Zhou T; Han X; Zhuang H; Qian H
Biochem Biophys Res Commun; 2015 Aug; 464(2):519-25. PubMed ID: 26159916
[TBL] [Abstract][Full Text] [Related]
40. Increased copy number at 3p14 in breast cancer.
Ljuslinder I; Malmer B; Golovleva I; Thomasson M; Grankvist K; Höckenström T; Emdin S; Jonsson Y; Hedman H; Henriksson R
Breast Cancer Res; 2005; 7(5):R719-27. PubMed ID: 16168117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
